Congress

The 12th World Congress on High-Speed Rail Was Held in Beijing

MODERN RAILWAYS 2025 Held Concurrently BEIJING, July 10, 2025 /PRNewswire/ -- A news report from China Daily: According to China…

1 week ago
ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatmentESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment

ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment

LONDON, June 28, 2025 /PRNewswire/ -- A team of international scientists has made a major leap forward in diabetes research…

3 weeks ago

FIS Athletes Commission strengthens global voice at FIS Congress and International Athletes Forum

Jun 25, 2025 - The FIS Athletes’ Commission (AC) continues to elevate the voice of athletes within the global snow…

4 weeks ago
Yili Secures Four World Dairy Innovation Awards at the 18th Global Dairy CongressYili Secures Four World Dairy Innovation Awards at the 18th Global Dairy Congress

Yili Secures Four World Dairy Innovation Awards at the 18th Global Dairy Congress

AMSTERDAM, June 23, 2025 /PRNewswire/ -- On June 18–19, the Global Dairy Congress 2025 was held in Amsterdam. At the forum,…

4 weeks ago
EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study findsEAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals…

4 weeks ago
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 CongressNovo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for…

4 weeks ago
Sharjah to Host World Congress for Inclusion 2025 — First Time in the Middle East and North African RegionSharjah to Host World Congress for Inclusion 2025 — First Time in the Middle East and North African Region

Sharjah to Host World Congress for Inclusion 2025 — First Time in the Middle East and North African Region

SHARJAH, UAE, June 17, 2025 /PRNewswire/ -- In a landmark moment for the region, the emirate of Sharjah will host the…

1 month ago
DBV Technologies to Participate in Upcoming EAACI Congress 2025DBV Technologies to Participate in Upcoming EAACI Congress 2025

DBV Technologies to Participate in Upcoming EAACI Congress 2025

Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN:…

1 month ago
RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 CongressRESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress

RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress

June 06, 2025 16:07 ET  | Source: Restem MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology…

1 month ago
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathyERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…

2 months ago